Apricoxib

Apricoxib
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide;
CAS Number	197904-84-0;
PubChem CID	9820073;
DrugBank	DB12378;
ChemSpider	7995822;
UNII	5X5HB3VZ3Z;
KEGG	D08657;
CompTox Dashboard (EPA)	DTXSID60173502 ;
Chemical and physical data
Formula	C19H20N2O3S
Molar mass	356.44 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C;
	InChI InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23); Key:JTMITOKKUMVWRT-UHFFFAOYSA-N;

Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID).^[1] It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer.^[2] It was also studied in clinical trials for non-small-cell lung cancer.^[3] Development was abandoned in 2015 due to poor clinical trial results.^[4]

References[]

^ "Apricoxib (Code C74021)". NCI Thesaurus. National Cancer Institute.
^ Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
^ Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, et al. (January 2015). "Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer". Journal of Clinical Oncology. 33 (2): 189–94. doi:10.1200/JCO.2014.55.5789. PMC 4890680. PMID 25452446.
^ "Apricoxib". Adis Insight. Springer Nature Switzerland AG.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by .

[1] "Apricoxib (Code C74021)". NCI Thesaurus. National Cancer Institute.

[2] Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012). "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer". Clinical Cancer Research. 18 (18): 5031–42. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.

[3] Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, et al. (January 2015). "Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer". Journal of Clinical Oncology. 33 (2): 189–94. doi:10.1200/JCO.2014.55.5789. PMC 4890680. PMID 25452446.

[4] "Apricoxib". Adis Insight. Springer Nature Switzerland AG.

[1]

[2]

[3]

[4]

Legal status

Legal status	Investigational
Identifiers
IUPAC name 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide
CAS Number	197904-84-0
PubChem CID	9820073
DrugBank	DB12378
ChemSpider	7995822
UNII	5X5HB3VZ3Z
KEGG	D08657
CompTox Dashboard (EPA)	DTXSID60173502
Chemical and physical data
Formula	C₁₉H₂₀N₂O₃S
Molar mass	356.44 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
InChI InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) Key:JTMITOKKUMVWRT-UHFFFAOYSA-N

Apricoxib

See also[]

References[]